Another box ticked, and another step closer building this company into a major biotech player. Next catalyst recruitment commenced? I suspect as we move further into the P3 trial the market will realise just how undervalued this stock is, at less than $250m, for a company with such a late stage drug for such a major indication (noting that Vertex added $20b (that’s billion with a B) AUD to its market cap in the week following FDA approval for its pain drug)
Ann: Paradigm Secures Ethics Approval for Phase 3 Trial, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.020(6.90%) |
Mkt cap ! $120.7M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 28.0¢ | $97.62K | 331.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 74197 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 54675 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| PAR (ASX) Chart |